Psychomotor depressive symptoms may differentially respond to venlafaxine

International Clinical Psychopharmacology

Volumn 28, Issue 3, 2013, Pages 121-126

  Singh, Ajeet B ^a,b   Bousman, Chad A ^b,c,e   Ng, Chee H ^b   Byron, Keith ^f   Berk, Michael ^a,b,c,d  

^a DEAKIN UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^f Healthscope Pathology   (Australia)

Author keywords

escitalopram; melancholia; norepinephrine transporter; pharmacogenetics; psychomotor retardation; venlafaxine

Indexed keywords

ESCITALOPRAM; NORADRENALIN TRANSPORTER; VENLAFAXINE;

ADULT; ARTICLE; CONTROLLED STUDY; CORE PSYCHOMOTOR SIGNS SCALE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; FEMALE; GENETIC POLYMORPHISM; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOMOTOR DEPRESSIVE SYMPTOM; PSYCHOMOTOR RETARDATION; RATING SCALE; REMISSION; RISK;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHOMOTOR AGITATION; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84875813966     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32835f1b9f     Document Type: Article

References (53)

1. Amara SG, Kuhar MJ (1993). Neurotransmitter transporters: recent progress.Annu Rev Neurosci 16:73-93.
2. Baffa A, Hohoff C, Baune BT, Muller-Tidow C, Tidow N, Freitag C, et al. (2010).Norepinephrine and serotonin transporter genes: impact on treatmentresponse in depression. Neuropsychobiology 62:121-131.
3. Béque JC, Lavoie N, de Montigny C, Debonnel G (1998). Affinities of venlafaxineand various reuptake inhibitors for the serotonin and norepinephrinetransporters. Eur J Pharmacol 349:129-132.
4. Berk M, Ng F, Dodd S, Callaly T, Campbell S, Bernardo M, Trauer T (2008).The validity of the CGI severity and improvement scales as measures ofclinical effectiveness suitable for routine clinical use. J Eval Clin Pract14:979-983.
5. Chang CC, Lu RB, Chen CL, Chu CM, Chang HA, Huang CC, et al. (2007). Lackof association between the norepinephrine transporter gene and majordepression in a Han Chinese population. J Psychiatry Neurosci 2:121-128.
6. Charney D (1998). Monoamine dysfunction and the pathophysiology andtreatment of depression. J Clin Psychiatry 59 (Suppl 14):11-14.
7. Debonnel G, Saint-André E, Hé bert C, de Montigny C, Lavoie N, Blier P (2007).Differential physiological effects of a low dose and high doses of venlafaxinein major depression. Int J Neuropsychopharmacol 10:51.
8. Dong C, Wong ML, Licinio J (2009). Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association withmajor depression and antidepressant response in Mexican-Americans. MolPsychiatry 14:1105-1118.
9. Dubini A, Bosc M, Polin V (1997). Noradrenaline-selective versus serotoninselectiveantidepressant therapy: differential effects on social functioning.J Psychopharmacol 11 (Suppl 4):17-23.
10. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. (2010). Antidepressant drug effects and depression severity: a patientlevelmeta-analysis. JAMA 303:47-53.
11. Fournier JC, DeRubeis RJ, Shelton RC, Hollon SD, Amsterdam JD, Gallop R(2009). Prediction of response to medication and cognitive therapy in thetreatment of moderate to severe depression. J Consult Clin Psychol 77:775-787.
12. Gaunt TR, Rodrguez S, Day INM (2007). Cubic exact solutions for the estimationof pairwise haplotype frequencies: implications for linkage disequilibriumanalyses and a web tool'CubeX'. BMC Bioinformatics 8:428.
13. Heninger G, Delgado P, Charney D (1996). The revised monoaminetheory of depression: a modulatory role for monoamines, based on newfindings from monoamine depletionexperiments in humans. Pharmacopsychiatry29:2-11.
14. Higuchi H, Yoshida K, Takahashi H, Naito S, Kamata M, Ito K, et al. (2003).Milnacipran plasma levels and antidepressant response in Japanese majordepressive patients. Hum Psychopharmacol 18:255-259.
15. Joyce PR, Mulder RT, Luty SE, McKenzie JM, Sullivan PF, Abbott RM, et al.(2002). Melancholia: definitions, risk factors, personality, neuroendocrinemarkers and differential antidepressant response. Aust N Z J Psychiatry36:376-383.
16. Kasper S (1997). The place of milnacipran in the treatment of depression. HumPsychopharmacol 12 (Suppl):135-141.
17. Keers R, Uher R, Huezo-Diaz P, Smith R, Jaffee S, Rietschel M, et al. (2011).Interaction between serotonin transporter gene variants and life eventspredicts response to antidepressants in the GENDEP project. PharmacogenomicsJ 11:138-145.
18. Khan A, Brodhead AE, Kolts RL, Brown WA (2005). Severity of depressivesymptoms and response to antidepressants and placebo in antidepressanttrials. J Psychiatr Res 39:145-150.
19. Khan A, Leventhal RM, Khan SR, Brown WA (2004). Severity of depression andresponse to antidepressants and placebo: an analysis of the Food and DrugAdministration database. J Clin Psychopharmacol 24:1-3.
20. Kim H, Lim SW, Kim S, Lim JW, Chang YH, Carroll BJ, et al. (2006). Monoaminetransporter gene polymorphisms and antidepressant response in Koreanswith late-life depression. JAMA 296:1609-1618.
21. Leonard B (1997). The role of noradrenaline in depression: a review. J Psychopharmacol11 (Suppl 4):39-47.
22. Leszczynska-Rodziewicz A, Czerski PM, Kapelski P, Godlewski S, Dmitrzak-Weglarz M, Rybakowski J, et al. (2002). A polymorphism of thenorepinephrine transporter gene in bipolar disorder and schizophrenia: lack ofassociation. Neuropsychobiology 45:182-185.
23. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987). The UKU sideeffect rating scale. A new comprehensive rating scale for psychotropic drugsand a cross-sectional study of side effects in neuroleptic-treated patients.Acta Psychiatr Scand 334:1-100.
24. Massana J, Mö ller HJ, Burrows GD, Montenegro RM (1999). Reboxetine:a double-blind comparison with fluoxetine in major depressive disorder. IntClin Psychopharmacol 14:73-80.
25. Mbaya P (2002). Safety and efficacy of high dose venlafaxine XL in treatmentresistant major depression. Hum Psychopharmacol 17:335-339.
26. Min W, Li T, Ma X, Li Z, Yu T, Gao D, et al. (2009). Monoamine transporter genepolymorphisms affect susceptibility to depression and predict antidepressantresponse. Psychopharmacology (Berl) 205:409-417.
27. Moncrieff J, Kirsch I (2005). Efficacy of antidepressants in adults. BMJ331:155-157.
28. Nanni V, Uhr R, Danese A (2012). Childhood maltreatment predicts unfavorablecourse of illness and treatment outcome in depression: a meta-analysis. Am JPsychiatry 169:141-151.
29. Nutt DJ (2008). Relationship of neurotransmitters to the symptoms of majordepressive disorder. J Clin Psychiatry 69 (Suppl E1):4-7.
30. Owen D, Du L, Bakish D, Lapierre YD, Hrdina PD (1999). Norepinephrinetransporter gene polymorphism is not associated with susceptibility to majordepression. Psychiatry Res 87:1-5.
31. Owens MJ (1997). Molecular and cellular mechanisms of antidepressant drugs.Depress Anxiety 4:153-159.
32. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB (1997). Neurotransmitterreceptor and transporter binding profile of antidepressant and theirmetabolites. J Pharmacol Exp Ther 283:1305-1322.
33. Parker G, Hadzi-Pavlovic D (1996). Melancholia: a disorder of movement andmood ISBN 0-521-47275-x. New York: Cambridge University Press.
34. Parker G, Mitchell P, Wilhelm K, Menkes D, Snowdon J, Schweitzer I, et al.(1999). Are the newer antidepressant drugs as effective as establishedphysical treatments? Results from an Australasian clinical panel review. AustN Z J Psychiatry 33:874-881.
35. Parker G, Roy K, Wilhelm K, Mitchell P (2001). Assessing the comparativeeffectiveness of antidepressant therapies: a prospective clinicalpractice study. J Clin Psychiatry 62:117-125.
36. Paykel ES, Hollyman JA, Freeling P, Sedgwick P (1988). Predictors of therapeuticbenefit from amitriptyline in mild depression: a general practice placebocontrolledtrial. J Affect Disord 14:83-95.
37. Porcelli S, Drago A, Fabbri C, Gibiino S, Calati R, Serretti A (2011). Pharmacogeneticsof antidepressant response. J Psychiatry Neurosci 36:87-113.
38. Potter W, Grossman G, Rudorfer M (1993). Noradrenergic function in depressivedisorders. In
39. Ressler KJ, Nemeroff CB (1999). Role of norepinephrine in the pathophysiologyand treatment of mood disorders. Biol Psychiatry 46:1219-1233.
40. Ryu SH, Lee SH, Lee HJ, Cha JH, Ham BJ, Han CS, et al. (2004). Associationbetween norepinephrine transporter gene polymorphism and major depression.Neuropsychobiology 49:174-177.
41. Samochowiec J, Kucharska-Mazur J, Kaminski R, Smolka M, Rommelschpacher H, Wernicke C, et al. (2002). Norepinephrine transporter gene polymorphism isnot associated with susceptibility to alcohol dependence. Psychiatry Res111:229-233.
42. Schatzberg A, Schildkraut J (1995). Recent studies on norepinephrine systems inmood disorders. In
43. Singh AB, Bousman CA, Ng CH, Byron K, Berk M (2012). ABCB1 polymorphismpredicts escitalopram dose needed for remission in major depression. TranslPsychiatry 2:e198.
44. Sogawa C, Mitsuhata C, Kumagai-Morioka K, Sogawa N, Ohyama K, Morita K, et al. (2010). Expression and function of variants of human catecholaminetransporters lacking the fifth transmembrane region encoded by exon 6. PLoSONE 5:1-13.
45. Sotsky SM, Glass DR, Shea TM, Pilkonis PA, Collins JF, Elkin I, et al. (1991).Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative ResearchProgram. Am J Psychiatry 148:997-1008.
46. Thase ME, Shelton RC, Khan A (2006). Treatment with venlafaxine extended releaseafter SSRI nonresponse or intolerance: a randomized comparison of standardandhigher-dosing strategies. J Clin Psychopharmacol 26:250-258.
47. Tse WS, Bond AJ (2002). Difference in serotonergic and noradrenergicregulation of human social behaviours. Psychopharmacology (Berl) 159:216-221.
48. Uher R, Huezo-Diaz P, Perroud N, Smith R, Rietschel M, Mors O, et al. (2009).Genetic predictors of response to antidepressants in the GENDEP project.Pharmacogenomics J 9:225-233.
49. Uhl GR, Johnson PS (1994). Neurotransmitter transporters: three important genefamilies for neuronal function. J Exp Biol 196:229-236.
50. Yoshida K, Takahashi H, Higuchi H, Kamata M, Ito K, Sato K, et al. (2004).Prediction of antidepressant response to Milnacipran by norepinephrinetransporter gene polymorphisms. Am J Psychiatry 161:1575-1580.
51. Zajecka JM (2003). Treating depression to remission. J Clin Psychiatry64:7s-12s.
52. Zill P, Engel R, Baghai TC, Juckel G, Frodl T, Muller-Siecheneder F, et al. (2002).Identification of a naturally occurring polymorphism in the promoter region ofthe norepinephrine transporter and analysis in major depression. Neuropsychopharmacology26:489-493.
53. Zittel S, Weiller C, Liepert J (2007). Reboxetine improves motor function inchronic stroke. A pilot study. J Neurol 254:197-201.